Delstrigo is a fixed-dose combination antiviral medication used to treat HIV-1 infection [1][2]. It contains three active ingredients: doravirine, lamivudine, and tenofovir disoproxil fumarate [1][2]. This combination works by preventing the human immunodeficiency virus from multiplying in the body [3].
What is doravirine, lamivudine, and tenofovir disoproxil fumarate?
Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) [4]. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) [5]. Tenofovir disoproxil fumarate is also an NRTI [6]. Together, these drugs target different stages of the HIV replication cycle [4][5][6].
How does Delstrigo work to treat HIV?
Delstrigo's three components work synergistically to inhibit HIV replication. Doravirine blocks the reverse transcriptase enzyme, which HIV needs to convert its RNA into DNA [4]. Lamivudine and tenofovir disoproxil fumarate act as chain terminators, preventing the synthesis of viral DNA [5][6]. By blocking viral replication, Delstrigo helps to lower the amount of HIV in a person's blood (viral load), which can improve immune system function [3].
When did Delstrigo become available?
Delstrigo was approved by the U.S. Food and Drug Administration (FDA) in February 2019 [1].
What are the common side effects of Delstrigo?
Common side effects reported in clinical trials include dizziness, nausea, fatigue, diarrhea, and rash [2]. Most side effects are generally mild to moderate and can often be managed [2].
How does Delstrigo compare to other HIV medications?
Delstrigo is a complete regimen in a single tablet, offering convenience for patients [1]. Its efficacy and safety profile are comparable to other antiretroviral therapies, and it is known for its favorable tolerability and lower risk of certain side effects compared to some older drugs [7][8]. For example, doravirine has been associated with a lower incidence of neuropsychiatric side effects compared to some other NNRTIs [8].
Are there any potential risks or contraindications for Delstrigo?
Delstrigo may cause serious side effects, including lactic acidosis, severe liver problems, and kidney problems [2]. Patients with pre-existing kidney disease or liver disease should discuss the risks with their healthcare provider [2]. It is also important to inform a doctor about all other medications being taken, as drug interactions can occur [2].
What is the patent status of Delstrigo?
The drug patent information for Delstrigo can be found on specialized databases. For detailed information on patent expiry dates and related intellectual property, resources like DrugPatentWatch.com are valuable [9].
Who manufactures Delstrigo?
Delstrigo is manufactured by Merck & Co. [1].